Literature DB >> 1319856

Noninvasive assessment of cardiomyopathy development with simultaneous measurement of topical 1H- and 31P-magnetic resonance spectroscopy.

T Toyo-oka1, K Nagayama, J Suzuki, T Sugimoto.   

Abstract

Background. It might be possible to estimate the metabolic derangement of cardiac muscle by topical nuclear magnetic resonance spectroscopy (MRS) in vivo without killing the animal. Methods and Results. By use of topical 1H- and 31P-MRS focused on the heart of Syrian hamsters with or without cardiomyopathy (CM; BIO 14.6 strain), the chemical constituents were measured in vivo nondestructively and repetitively at several stages of development of CM. A phantom experiment and two-dimensional plot of chain methylenes (CH2) of lipid/water ratio by 1H-MRS versus creatine phosphate (CP)/[beta-P]ATP ratio by 31P-MRS indicated that signal cross talk from the adjacent organs was negligible. Even before the onset of clinical or pathological manifestation of CM (7 weeks after birth), CH2/water ratio by 1H-MRS was lower in the CM group (7.3 +/- 0.7%) than in control (11.8 +/- 2.0%, p less than 0.05), and it decreased further at the hypertrophic stage (17 weeks, 4.1 +/- 0.7%, p less than 0.05) and the congestive stage (27 weeks, 4.3 +/- 0.9%, p less than 0.05). In contrast, the CP/[beta-P]ATP ratio by 31P-MRS started to decrease at the hypertrophic stage (1.90 +/- 0.18 versus 2.52 +/- 0.24, p less than 0.05) and decreased further at the congestive stage to 1.53 +/- 0.18 (p less than 0.01). These in vivo MRS data were confirmed by both biochemical assay and in vitro MRS analysis in heavy water after the animals were killed. Conclusions. A combination of topical 1H-MRS and 31P-MRS in vivo is promising for the noninvasive and sensitive assessment of cardiac muscle metabolism. Comparison of these MRS studies and biochemical analysis suggested not only the modification of water, lipid, CP, or ATP contents but also the reduction of flexibility or fluidity of lipids in cardiomyopathic heart.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1319856     DOI: 10.1161/01.cir.86.1.295

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  5 in total

1.  Rescue of hereditary form of dilated cardiomyopathy by rAAV-mediated somatic gene therapy: amelioration of morphological findings, sarcolemmal permeability, cardiac performances, and the prognosis of TO-2 hamsters.

Authors:  Tomie Kawada; Mikio Nakazawa; Sakura Nakauchi; Ken Yamazaki; Ryoichi Shimamoto; Masashi Urabe; Jumi Nakata; Chieko Hemmi; Fujiko Masui; Toshiaki Nakajima; Jun-Ichi Suzuki; John Monahan; Hiroshi Sato; Tomoh Masaki; Keiya Ozawa; Teruhiko Toyo-Oka
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

2.  Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, delta-sarcoglycan, in hamster: an animal model of disrupted dystrophin-associated glycoprotein complex.

Authors:  A Sakamoto; K Ono; M Abe; G Jasmin; T Eki; Y Murakami; T Masaki; T Toyo-oka; F Hanaoka
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

3.  Translocation and cleavage of myocardial dystrophin as a common pathway to advanced heart failure: a scheme for the progression of cardiac dysfunction.

Authors:  Teruhiko Toyo-Oka; Tomie Kawada; Jumi Nakata; Han Xie; Masashi Urabe; Fujiko Masui; Takashi Ebisawa; Asaki Tezuka; Kuniaki Iwasawa; Toshiaki Nakajima; Yoshio Uehara; Hiroyuki Kumagai; Sawa Kostin; Jutta Schaper; Mikio Nakazawa; Keiya Ozawa
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-05       Impact factor: 11.205

Review 4.  Cardiac 1H-MR spectroscopy.

Authors:  M von Kienlin
Journal:  MAGMA       Date:  1998-09       Impact factor: 2.533

5.  Pigs with δ-sarcoglycan deficiency exhibit traits of genetic cardiomyopathy.

Authors:  Hitomi Matsunari; Michiyo Honda; Masahito Watanabe; Satsuki Fukushima; Kouta Suzuki; Shigeru Miyagawa; Kazuaki Nakano; Kazuhiro Umeyama; Ayuko Uchikura; Kazutoshi Okamoto; Masaki Nagaya; Teruhiko Toyo-Oka; Yoshiki Sawa; Hiroshi Nagashima
Journal:  Lab Invest       Date:  2020-02-14       Impact factor: 5.662

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.